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The 2014–2016 Ebola Virus Disease (EVD) outbreak highlighted the vital importance of investing 
in West Africa’s laboratory infrastructure and systems. In the absence of facilities capable of 
handling highly infectious pathogens, the national response across the region was hamstrung by 
costly delays in case identification and blind spots in epidemiological surveillance. The rapid 
development of EVD diagnostic tools that could speed up testing and be used at or near the 
point of care became a public health priority. To expedite their deployment, a series of cross-
sectional research and development initiatives were launched including innovative financing 
mechanisms, data-sharing platforms, public-private partnerships and accelerated regulatory 
pathways.1
A number of novel EVD diagnostics were trialled in Sierra Leone.2,3,4,5,6,7 Guided by a national 
testing algorithm, rapid diagnostic tests (RDTs) such as ReEBOV (Corgenix, Broomfield, Colorado, 
United States) and the OraQuick (Orasure Technologies, Bethlehem, Pennsylvania, United States), 
intended for use at the primary care level, and automated real-time reverse transcription 
polymerase chain reaction (RT-PCR), primarily run on the benchtop, underwent rapid validation 
and performance evaluation through the World Health Organization’s Emergency Use and 
Assessment Listing mechanism.8,9,10,11 The ReEBOV test was temporarily deployed in a field 
setting in Sierra Leone and another rapid test, the DSTL EVD Rapid Diagnostic Antigen Test, 
developed by the Defence Science Technology Laboratory in the United Kingdom, was validated 
in hospital and primary care settings.6 However, biosafety concerns, related to challenges in 
procuring, distributing and providing training for the use of personal protective equipment to 
safely draw, handle and dispose of blood samples suspected of being infected with Ebola virus, in 
addition to imperfect sensitivity and specificity, meant RDTs were rarely used outside the 
laboratory. Instead, they were deployed at laboratories in key areas of the country alongside 
automated RT-PCR machines, such as GeneXpert (Cepheid, AB, Sunnyvale, California, United 
States) and BioFire Film Array (BioFire Diagnostics, Salt Lake City, Utah, United States), that 
could quickly confirm their results. In addition to commercially available platforms, international 
public health agencies and non-governmental organisations brought their own in-house assays, 
some of which came to provide a point of reference for field evaluations of novel tests.12 
Collectively, these advances in rapid and proximate point-of-care diagnostic capacity helped 
bring the outbreak to an end and became the cornerstone of Sierra Leone’s enhanced surveillance 
plan, intended to sustain a ‘resilient zero’ number of cases.13 
In the aftermath of Ebola, some of these devices and machines were left in clinical and surveillance 
laboratories as part of the post-Ebola effort to improve disease detection and response capabilities. 
An RT-PCR machine in the biosafety level 3 laboratory supported by the China Center for Disease 
Control and Prevention (China CDC) currently serves the Freetown area, while a GeneXpert 
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machine for point-of-care testing supports upcountry EVD 
surveillance in the Bo and Makeni Government Laboratories. 
While important for future outbreak response, the availability 
of EVD diagnostics is clearly only a minor part of public 
health emergency resilience.14 The handover of epidemic 
preparedness from international partners to national 
institutions offers a unique opportunity to think through the 
broader, system-level needs for the accurate and rapid 
diagnosis of infectious diseases. Critically, more attention is 
needed to grasp how national strategic plans for strengthening 
laboratory infrastructure can be best adapted to and advanced 
by the 2024 Global Health Security Agenda.15
Global health and policy debates, largely dominated by 
institutions in Europe and the United States, have focused on 
the development of new diagnostic technologies appropriate 
for resource-poor settings, which generally means that tests 
should be affordable, easy to use, rapid, and available at the 
point of care.16,17,18 Less prominent in these discussions are the 
voices of experts in laboratory medicine from the countries 
for which the rapid tests are designed. The experience of 
Sierra Leonean laboratory medicine experts, both during and 
after the outbreak, offers a valuable, under-recognised and 
much-needed perspective on the role of point-of-care tests 
and diagnostic innovation in global health.
On 04 March 2019, a multidisciplinary group of policymakers, 
biomedical and social scientists and local experts in the field 
of laboratory medicine convened to discuss the role of point-
of-care diagnostic devices in outbreaks and their integration 
with healthcare infrastructure in Sierra Leone. The meeting 
was organised by the DiaDev research project, funded by 
the European Research Council under the Horizon 2020 
Framework, which investigates the development of point-
of-care diagnostic devices in global health and their role in 
transforming health systems in resource-constrained settings 
(www.diadev.eu). The meeting featured short presentations 
as well as a panel discussion with Sierra Leonean laboratory 
scientists and health workers, who shared their first-hand 
experience using rapid diagnostic tests during the Ebola 
outbreak. Three key insights from the day are highlighted 
here as disruptive and constructive contributions to debates 
about diagnostic futures in Africa.
Diagnostic systems not diagnostics
Point-of-care devices are often championed as solutions for 
places with weak or no laboratory infrastructure. For EVD 
alone, there are up to 27 assays at different stages of 
development or use, including 9 antigen-based rapid tests 
and 18 RT-PCR assays for EVD.19 But the lower sensitivity of 
point-of-care devices means they are often integrated into 
complex algorithms that require confirmatory testing prior to 
treatment, which necessitates a wider public health laboratory 
network. Moreover, even in the case of tests approved for 
stand-alone use, routine quality assurance systems require 
proficiency training and regular cross-checking of samples 
by a reference laboratory. 
Lessons from Sierra Leone show that effective use of point-
of-care devices also depends on the existence of regulatory 
capacity to safeguard the quality of point-of-care devices. 
Many RDTs on the Sierra Leonean market are of questionable 
quality and have not passed through the Pharmacy Board, 
the agency that regulates medicines and diagnostics. 
Representatives of the Ministry of Health and Sanitation 
underscored that, while the Central Public Health Reference 
Laboratory is mandated with overseeing quality assurance 
and post-market validation of diagnostic tests for specific 
diseases such as HIV, there is a need to expand regulatory 
and quality assurance systems for all diagnostics, especially 
those for the national priority special pathogens. One 
current priority for the Central Public Health Reference 
Laboratory is to improve the post-market regulatory control 
by re-introducing lot verification testing of diagnostic devices 
before and after they are distributed to clinical settings. 
Enhancing these systems will curtail the supply of low-
standard tests and also empower national clinical and public 
health systems to demand more rigorously tested and, 
arguably, superior products from international vendors. 
Moreover, further investigation is needed into how these 
devices are being used in clinical practice and their capacity 
to improve patient care. For example, in the country’s main 
referral hospital, rapid tests for hepatitis B, Helicobacter pylori 
and urine analysis, are used inside the clinical laboratory, but 
routine reporting systems in the laboratory mean results are 
only given back to clinicians the next day, even when the test 
result is ready earlier, impacting the ability of point-of-care 
tests to reduce result turn-around times. The migration of 
rapid diagnostic technologies into clinical laboratories also 
poses the risk that technologies designed to provide 
preliminary clinical diagnosis in places without laboratories 
actually replace and diminish existing laboratory capacity. 
Point-of-care tests do not present an alternative to investment 
in central laboratories, which remain essential for quality 
assurance, confirmatory testing and research.20 Particularly 
among patient populations likely to be afflicted by more than 
one disease, the availability of a comprehensive suite of basic 
laboratory tests located at a primary care level, as outlined by 
the World Health Organization’s recently published Essential 
Diagnostics List,21 is critical to the establishment of person-
centred healthcare. Rather than asking whether we should 
invest in laboratory strengthening or point-of-care tests, we 
need to look at how we can best build diagnostic systems and 
what role new diagnostic technologies might play in 
strengthening those systems. 
The World Health Organization framework for health 
systems strengthening has drawn critical attention to the six 
technical ‘building blocks’ of health systems: service delivery, 
health workforce, information, medical products, financing, 
and leadership and governance.22 All these areas are 
fundamental to the operation of a diagnostic system, whether 
this means training the health workforce in the use of new 
diagnostic devices, ensuring health information systems are 
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aligned with the data from new diagnostic devices, securing 
supply systems to ensure reagents and other equipment are 
at hand, or building quality assurance systems that connect 
peripheral health facilities to central laboratories. But while 
the World Health Organization framework focuses on 
technical elements, our on-the-ground experience of 
laboratory medicine in Sierra Leone emphasises the 
relationships between people, technologies and infrastructure 
that enable diagnostic systems to work. These relationships 
are social and political, as well as technical, and their 
understanding requires attention to the interaction between 
local and global normative frameworks and value systems in 
addition to formal management structures.23 Building on 
the work of social scientists working in this area, we propose 
that systems thinking entails a shift away from a focus 
on diagnostic technologies to understanding the way 
relationships between people, technologies and infrastructure 
unfold within everyday diagnostic processes and practices.24
The hidden burdens of technology
Recent global health policy discussions about diagnosis in 
low- and middle-income countries have focused on the need 
to incentivise markets for new diagnostic technologies. Point-
of-care tests that can be sold as affordable products are often 
championed as simple and easy-to-use solutions for places 
with limited infrastructure. But the Sierra Leonean experience 
suggests that new technologies also place a significant un-
costed burden on the health system and the people who work 
in it, reinforcing the existing findings from social science 
research that point-of-care tests in Africa have unexpected, 
intensive infrastructure requirements.25,26
Contributors to the workshop noted that the burden is most 
sharply felt in supply chains, especially around the need for 
a constant and reliable supply of reagents, and transportation 
costs for confirmatory testing as part of quality assurance. In 
a recent measles outbreak in Sierra Leone in 2018, limited 
resources for specimen transportation to the reference 
laboratory from districts, provided through the national 
surveillance programme, and the lack of a full complement 
of reagents for analysis, hampered timely diagnosis. In this 
instance, preliminary diagnosis with a point-of-care test may 
have provided a stopgap for a quicker response. However, 
the 2012–2013 cholera outbreak in Sierra Leone showed 
that point-of-care tests often lack the required sensitivity, 
with only 10% of cases confirmed positive by conventional 
culture in the bacteriology laboratory, resulting from 
weak international and national regulatory frameworks 
safeguarding the quality of cholera RDTs.27 Point-of-care 
tests with very high sensitivity and specificity need to be 
coupled with confirmatory testing infrastructure and proper 
coordination between government institutions with oversight 
roles to ensure that the right types of kits are used for routine 
diagnosis. 
Beyond the compromises in accuracy that point-of-care test 
designs often entail, every new diagnostic device and each 
iteration of platforms already in use requires a retraining of 
health workers and laboratory staff, creating heavy logistical, 
administrative and financial costs on public health 
institutions. These expenditures are compounded by those 
associated with the routine operations of the laboratory, 
including the purchasing of equipment, reagents, storage 
of large volumes of tests that require refrigeration, 
everyday maintenance and, critically, management of non-
biodegradable waste, generated by point-of-care tests such as 
the cartridges used in GeneXpert machines or the test 
cassettes holding reagent strips for viral hepatitis tests. In the 
past, these institutional overhead costs have been mainly 
supported by donors as part of short-term research budgets. 
To support efforts to improve quality-assured diagnostic 
operations, a clearer understanding is needed of the hidden 
costs of diagnostics and where they fit in the broader financial 
landscape of national laboratory infrastructure and systems. 
What is diagnosis for?
Diagnostic testing is not a medical intervention, but a means 
of generating information for evidence-based medical 
practice. The question we must ask is: what can be done with 
this information in this place, with these resources, by these 
people? The point of diagnosis is not just to know what 
disease someone has, but to be able to act on that knowledge – 
whether in terms of public health measures or therapeutic 
intervention. As the panellists in a round table discussion 
dedicated to reflections on the use of point-of-care tests 
during the EVD outbreak made clear, detecting the presence 
of a pathogen is just one component in a larger set of testing 
needs. Diagnosing EVD is key to public health measures, 
such as the isolation of patients, safe burial of bodies and 
contact tracing, but for clinicians it is only the starting point 
for therapeutic intervention. When it comes to care, other 
tests, such as liver function or electrolytes are arguably more 
important and depend on a generalised laboratory capacity. 
For example, point-of-care bedside analysers, such as the 
i-STAT (Abbott, Lake Forest, Illinois, United States), which 
can help monitor patients in the red zone of the treatment 
unit, were crucial to saving lives during the outbreak but 
received far less attention than Ebola diagnostics. Intermittent 
power outages can affect the validity of standard laboratory 
tests, such as blood culture, with dangerous implications 
for clinical outcomes during routine care practices but also 
poses a significant challenge for clinicians working during 
the outbreak. 
Finally, as we look ahead towards building a sustainable 
healthcare laboratory system in Sierra Leone, we need to link 
the question of diagnostic use to that of diagnostic value, or 
‘what worth does a specific diagnostic test have for the 
particular health system?’ At a cost-effectiveness level, 
answering this question might mean calculating in the 
hidden burdens that new technologies generate, including 
workload burdens involved in using tests and reporting 
results, burdens on patients to travel for testing, and burdens 
on the health system to provide training, quality assurance, 
regulation, procurement and supply, and waste disposal 
systems. Some point-of-care tests may reduce the cost of care 
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in wealthy countries but are a burden in resource-constrained 
countries such as Sierra Leone.28 For example, point-of-care 
PCR tests, such as the BioFire Film Array system and 
GeneXpert machines, require the use of expensive cartridges 
that deter their routine use for testing; the cost of a BioFire 
Gastro-intestinal panel ($155.00) is higher than the minimum 
monthly wage in Sierra Leone.28
Calculations of value would caution against the hasty 
introduction of new, more advanced testing devices for 
particular diseases, when local capacity for testing already 
exists. For instance, investing in simple and affordable 
technology such as ammonia solution for assessment of 
haemoglobin using a colorimeter may offer better value for 
money than handheld point-of-care haemoglobin meters 
with costly cuvettes (e.g. HemoCue, Ängelholm, Sweden), 
which also require the training of laboratory staff and 
placement in coordinated systems. As another example, 
while biosequencing may be a compelling orientation for 
research on emerging infections, for clinical use in a resource-
poor context, its running costs are plainly prohibitive. 
The value of a diagnostic test cannot be determined merely 
by the accuracy of the test or the global health priority of the 
pathogen but on the basis of local needs and consideration of 
the test’s clinical and operational benefits. The work that the 
Viral Hemorrhagic Fever Consortium did in partnering with 
a local institution in the design and development of an RDT 
for Lassa fever virus is an example of how local priorities can 
be built into innovation processes from the outset and such 
local institutional partnerships are to be encouraged in 
the development of future diagnostic systems in African 
countries.29 A novel diagnostic test’s value, moreover, is 
not the same as its value for money. Beyond a bottom-line 
economic analysis, the adjudication of diagnostic value 
requires attention to the everyday lives and work of patients, 
clinicians, nurses, laboratory technicians, surveillance officers 
and public health officials.
Conclusion 
Point-of-care tests are never introduced in a vacuum. Ebola 
brought visibility to the need for improved diagnostic 
systems in low- and middle-income countries, but even 
countries severely lacking in laboratory infrastructure have 
pre-existing and highly specific diagnostic needs and 
capacities. Sierra Leone had a National Medical Laboratory 
Policy and five-year strategic plan in place when the Ebola 
outbreak occurred. While the renewed focus on global health 
security strengthening and, by extension, laboratory system 
improvement, is welcome, it is critical that the national tools 
and plans put in place are aligned to any new diagnostic 
devices or laboratory strengthening initiatives and allow for 
national priorities to be addressed.
Point-of-care diagnostic devices are often championed for 
their ability to work anywhere, but technologies are never 
autonomous from the systems in which they are used. 
Diagnostic innovation needs to start from existing diagnostic 
systems and national policies and plans. This requires the 
involvement of social science research in understanding the 
local context into which point-of-care testing devices are 
introduced and in identifying local priorities for 
strengthening diagnostic systems. Global health research and 
development should be directed at making diagnostic 
systems become workable in their own right, rather than 
finding ways that an ever-increasing range of individual 
technologies can be best accommodated.
Post-Ebola, Sierra Leone is focused on improving the resilience 
of healthcare delivery.30 This goal will require building a 
diagnostic system that can prepare for and respond to ‘health 
shocks’, such as outbreaks and natural disasters, and also 
withstand the chronic stresses that accompany long-term 
resource constraints.31 A systems approach that encompasses 
both emergency and long-term timeframes needs to be 
present at the outset of the diagnostic development process, 
not only at the point at which new technologies are deployed. 
Most importantly, diagnostic futures need to be designed 
with the input of the people who work in and use them and 
they need to incorporate the insight that local experts have 
gained on the front line of global health innovation.
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